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Introduction {#sec001}
============

Tuberculosis (TB) is currently the leading cause of death from a single infectious agent \[[@ppat.1008287.ref001]\]. The limitations of current treatment regimens, combined with the rapid emergence of multidrug-resistant tuberculosis (MDR-TB) strains, necessitate the development of new drugs. Three new antitubercular agents are now in advanced clinical development: bedaquiline and delamanid \[[@ppat.1008287.ref002]\], which have been conditionally approved for MDR-TB treatment \[[@ppat.1008287.ref003],[@ppat.1008287.ref004]\], and pretomanid \[[@ppat.1008287.ref005]\], which is approved as part of a promising regimen containing bedaquiline and linezolid (<http://www.newtbdrugs.org/pipeline/clinical>). The nitroimidazoles, delamanid and pretomanid, are prodrugs that are reductively activated in an F~420~H~2~-dependent reaction in *Mycobacterium tuberculosis* by deazaflavin-dependent nitroreductase (Ddn) \[[@ppat.1008287.ref006],[@ppat.1008287.ref007]\]. An initial hydride transfer step from the F~420~H~2~ cofactor leads to their decomposition into *des*-nitro products and releases reactive nitrogen species that elicit a bactericidal mode-of-action linked to respiratory poisoning and inhibition of mycolic acid synthesis \[[@ppat.1008287.ref006]--[@ppat.1008287.ref008]\].

Because pretomanid and delamanid are prodrugs that require activation, mutations that knock-out the activity of Ddn or the biosynthesis or reduction of the enzyme's cofactor (F~420~), could confer resistance. However, the fitness cost of such knockouts may be considerable given that (i) F~420~ has been shown to be conditionally essential to the survival of *M*. *tuberculosis*, (ii) F~420~ is required by at least 28 different enzymes \[[@ppat.1008287.ref009]\], and (iii) it plays important roles in hypoxic survival, protection against oxidative and nitrosative damage, and evasion of the host immune system \[[@ppat.1008287.ref010]--[@ppat.1008287.ref012]\]. Ddn is highly conserved across almost all species of mycobacteria (except *Mycobacterium leprae*), suggesting its physiological role is under strong evolutionary selection \[[@ppat.1008287.ref013]\]. It has been hypothesised that Ddn serves as an F~420~H~2~-dependent menaquinone reductase given its membrane localisation and catalytic activity with the synthetic quinone analogue menadione \[[@ppat.1008287.ref012],[@ppat.1008287.ref014]\], although further work is required to fully define its physiological role.

Despite the recent introduction of nitroimidazoles, cases of acquired clinical resistance, i.e. resistance that occurs during the long treatment of TB infection but is not necessarily transmissible, have already been reported \[[@ppat.1008287.ref015],[@ppat.1008287.ref016]\]. Acquired resistance to pretomanid and delamanid can occur through genetic changes that cause loss of function within the biosynthetic pathway for F~420~ production or in the F~420~-dependent glucose 6-phosphate dehydrogenase (FGD) that catalyzes F~420~ reduction to F~420~H~2~ \[[@ppat.1008287.ref017],[@ppat.1008287.ref018]\]. Laboratory studies have also shown that genetic changes that abolish Ddn activity can also confer resistance \[[@ppat.1008287.ref018]--[@ppat.1008287.ref020]\]. While such mutations could compromise treatments for individuals that are already infected, transmission of *M*. *tuberculosis* to healthy individuals after these genetic changes has never been documented. We speculate that in order to for tuberculosis to spread effectively and endanger health, these resistant strains would need to retain sufficient fitness to survive all stages of the lifecycle of *M*. *tuberculosis*, including recovery from hypoxia. Interestingly, delamanid-resistant isolates with mutations in *ddn* have been recovered from MDR-TB patients who never received delamanid or pretomanid \[[@ppat.1008287.ref021],[@ppat.1008287.ref022]\], raising important questions about the fitness costs associated with such mutations and their potential impact on transmission.

In this study, we analysed Ddn orthologs from related mycobacteria to identify natural sequence variations that make mycobacteria resistant to pretomanid, as well as analysing the genomes of \~15,000 *M*. *tuberculosis* isolates to identify the spectrum of naturally occurring non-synonymous Ddn polymorphisms. Mutations were then made to Ddn at positions identified in orthologs and through analysis of non-synonymous polymorphisms to analyse their effect on the native activity (quinone reduction) and pretomanid activation. Altogether, 75 mutants, at 47 unique positions within the 151 amino acid Ddn protein were analysed. This identified a number of mutations that prevent pretomanid/delamanid activation, without full loss of the native menaquinone reductase activity. Analysis of complete and partial Ddn knock-outs demonstrated that it is essential for resuscitation from hypoxia, i.e. genetic variants that have lost their nitroimidazole-activation function, but retained their native activity, appear to be sufficiently fit to spread and cause disease in new patients. We examined a hypervirulent strain of *M*. *tuberculosis* from Vietnam that contains one such mutation (despite never being exposed to pretomanid), which is resistant to pretomanid. Curiously, sensitivity to delamanid activation was not affected in this strain, nor was delamanid activation by the Ddn variant *in vitro*, which is consistent with our structural analysis that suggests it binds to the active site of Ddn in an alternative orientation.

Results {#sec002}
=======

The physiological role of Ddn {#sec003}
-----------------------------

A role for Ddn as a quinone reductase was previously suggested based on activity with the synthetic menaquinone analogue menadione \[[@ppat.1008287.ref012]\]. Here, we show that purified Ddn catalyzes the F~420~H~2~-dependent reduction of menaquinone, which is known to accept electrons from a variety of electron donors and transfer them to terminal oxidases or reductases in mycobacterial respiration \[[@ppat.1008287.ref023]\]. Ddn catalyzed menaquinone-1 reduction *in vitro* with a *k*~cat~/*K*~M~ value of \~10^3^ M^-1^ s^-1^ and a *K*~M~ of 22.4 ± 3.8 μM ([Fig 1a](#ppat.1008287.g001){ref-type="fig"}, [Table 1](#ppat.1008287.t001){ref-type="table"}). It should be noted that the catalytic rate is likely to be higher in the crowded native environment of the *M*. *tuberculosis* cell where Ddn and menaquinone are co-localised at the cell membrane \[[@ppat.1008287.ref024]\]. The enzyme kinetics of Ddn are comparable to another mycobacterial menaquinone oxidoreductase, MenJ (Rv0561c), which is found in the menaquinone biosynthetic pathway (*k*~cat~/*K*~M~ of \~10^4^ M^-1^ s^-1^ and *K*~M~ of 30 μM \[[@ppat.1008287.ref025]\]). The *K*~M~ value is significantly lower than the median *K*~M~ of enzymes with their native substrates (\~130 μM), and the *k*~cat~/*K*~M~ value is within the broad distribution of known enzymes (10^3^−10^7^ M^-1^ s^-1^), albeit at the lower end of the range \[[@ppat.1008287.ref026],[@ppat.1008287.ref027]\]. Ddn orthologs encoded by *Mycobacterium smegmatis* (MSMEG_2027, MSMEG_5998) were also able to reduce menaquinone, suggesting that Ddn orthologs have similar physiological roles across the genus ([Table 1](#ppat.1008287.t001){ref-type="table"}). Indeed, Ddn and its orthologs are highly conserved and abundant throughout mycobacteria \[[@ppat.1008287.ref013]\].

![Ddn is a respiratory primary dehydrogenase that couples F~420~H~2~ oxidation to menaquinone reduction.\
**A**. Michaelis-Menten curve of the activity of purified Ddn with menaquinone-1 in the presence of F~420~H~2~. Rates were determined by measuring change of absorbance at 420 nm. Error bars indicate SEM (n = 3). **B**. Relative oxygen consumption of *M*. *smegmatis* membranes. F~420~, NADH, and glucose 6-phosphate were present in all assays, while the availability of the F~420~-dependent glucose 6-phosphate dehydrogenase (FGD) was varied. Membranes were purified from four different genetic backgrounds: wild-type, a transformant with the empty complementation vector pMV261, a transformant with pMV261 expressing the *ddn* gene, and a strain containing a chromosomal cytochrome *bd* oxidase deletion (Δ*cydA*). Error bars indicate SEM (n = 3). Stars above each column indicate a statistically significant difference compared to the first column. Other significant differences are shown by starred lines between columns. \* = p ≤ 0.05, \*\* = p ≤ 0.01, \*\*\*\* = p ≤ 0.0001 n.s = p \> 0.05 (one-way ANOVA followed by Tukey's multiple comparison test). **C**. Rate of NADH oxidation in the presence and absence of F~420~H~2~. Rates were determined by following change of absorbance at 340 nm. n.s indicates p \> 0.05, two tailed t-test, error bars indicate SEM (n = 3).](ppat.1008287.g001){#ppat.1008287.g001}
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###### Kinetic parameters of native F~420~H~2~-dependent menaquinone reductase activities of Ddn and *M*. *smegmatis* orthologs in *in vitro* assays.

![](ppat.1008287.t001){#ppat.1008287.t001g}

               Menaquinone                             
  ------------ ------------------------- ------------- -----------
  Ddn          1.9×10^−2^ ± 9.7×10^−4^   22.4 ± 3.8    8.6×10^2^
  MSMEG_2027   5×10^−3^ ± 1.2×10^−3^     80.7 ± 34.4   6.1×10^1^
  MSMEG_5998   1.2×10^−2^ ± 1.5×10^−3^   97.9 ± 20.4   1.2×10^2^

Having established that Ddn can reduce menaquinone with efficiency that could be physiologically relevant, along with the fact that menaquinone is the only native quinone in *M*. *tuberculosis* \[[@ppat.1008287.ref028]--[@ppat.1008287.ref030]\], we then investigated whether the menaquinone reductase activity of Ddn was coupled to the mycobacterial respiratory chain by comparing the rates of respiratory oxygen consumption of *M*. *smegmatis* in the presence and absence of a complementation vector expressing *ddn*. We observed that the addition of glucose 6-phosphate (G6P), F~420~, and F~420~ dependent glucose-6-phosphate dehydrogenase (FGD), which catalyzes the reduction of F~420~ to F~420~H~2~ for use by F~420~H~2~-dependent enzymes such as Ddn \[[@ppat.1008287.ref031]\], resulted in a statistically significant increase in oxygen consumption by mycobacterial membranes when the membranes are activated by NADH ([Fig 1b](#ppat.1008287.g001){ref-type="fig"}). This was dependent on the presence of cytochrome *bd* oxidase, which utilizes reduced menaquinone (i.e. menaquinol) as an electron source ([Fig 1b](#ppat.1008287.g001){ref-type="fig"}). The rate of NADH oxidation was not affected by the addition of F~420~H~2~ in the absence of *ddn*, which implies endogenous NADH-dependent oxidases do not contribute to the increased oxygen consumption ([Fig 1c](#ppat.1008287.g001){ref-type="fig"}). This supports the idea that mycobacteria can couple F~420~H~2~ oxidation to O~2~ reduction through the respiratory chain *via* cytochrome *bd* oxidase and demonstrates that bacteria can use F~420~H~2~ as a respiratory electron donor. We also observed that the extent of oxygen consumption was significantly higher in membranes purified from the strain that expressed *ddn*, relative to empty vector controls ([Fig 1b](#ppat.1008287.g001){ref-type="fig"}), which suggest Ddn serves as a menaquinone reductase in the respiratory chain, with the remaining stimulation attributable to F~420~H~2~ oxidation by native Ddn homologs of *M*. *smegmatis*. Altogether, these results suggest that Ddn likely plays a role in bacterial respiration through reduction of menaquinone.

Natural sequence variation in Ddn can result in loss of pretomanid activation with retention of the native activity {#sec004}
-------------------------------------------------------------------------------------------------------------------

Having established that Ddn is a menaquinone reductase, we then investigated the effects of natural sequence variation within Ddn orthologs from mycobacteria on the native, and drug-activating, activities. We expressed and purified Ddn orthologs from *M*. *tuberculosis*, *M*. *marinum*, *M*. *smegmatis*, *M*. *vanbaalenii*, *M*. *avium* and *M*. *ulcerans*. All Ddn orthologs catalyzed the reduction of menadione, suggesting that this is a shared physiological function that has been under consistent selective pressure. However, only Ddn from *M*. *tuberculosis* and *M*. *marinum* could activate pretomanid ([Fig 2a](#ppat.1008287.g002){ref-type="fig"}, [Table 2](#ppat.1008287.t002){ref-type="table"}). This demonstrates that the native Ddn activity can exist in in the absence of nitroimidazole reductase activity, i.e. the drug-activating activity is not coupled to the native activity. The binding site of Ddn has been defined over several studies, identifying a number of polar amino acids within the substrate binding site that contribute to activity, particularly Y65, S78, Y130, Y133, Y136 ([Fig 2b](#ppat.1008287.g002){ref-type="fig"}). Three of these binding site residues are fully conserved among the Ddn orthologs tested here, whereas Y65 and Y133 are more variable ([Fig 2c](#ppat.1008287.g002){ref-type="fig"}). These results show that sequence variation among Ddn orthologs in mycobacteria can result in the loss of the promiscuous, nitroimidazole-activating activity.

![The activity of Ddn and orthologs from other mycobacterial species and key substrate binding pocket residues.\
**(a)** The activity of Ddn and orthologs with menadione, pretomanid, and delamanid. Error bars show standard deviations from three independent replicates. **(b)** Multiple sequence alignment of Ddn and orthologs. Highlighted residues indicate active site residues and numbers indicate their residue position in Ddn. **(c)** The binding pocket of Ddn consists of F~420~/F~420~H~2~, Tyr65, Ser78, Tyr130 and Tyr136.](ppat.1008287.g002){#ppat.1008287.g002}
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###### Reduction rates of F~420~H~2~-dependent menadione and nitroimidazole reductase activities of Ddn mutants.

![](ppat.1008287.t002){#ppat.1008287.t002g}

                                                                                         Rate of Reaction (nmol min^-1^ μmol~enzyme~^-1^)[^a^](#t002fn003){ref-type="table-fn"}                              
  -------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- -------------------------- --------------------------
  *M*. *tuberculosis* mutants selected for pretomanid resistance in laboratory                                                                                                                               
  M1T                                                                                    N/A                                                                                      N/A                        N/A
  S22L                                                                                   5.03×10^2^ ± 4.34×10^1^                                                                  N/D                        N/D
  L49P[\*](#t002fn002){ref-type="table-fn"}                                              4.99×10^1^ ± 7.87                                                                        N/D                        N/D
  L64P                                                                                   4.13×10^1^ ± 1.12                                                                        N/D                        N/D
  W88R[\*](#t002fn002){ref-type="table-fn"}                                              2.16×10^1^ ± 7.18×10^−2^                                                                 N/D                        N/D
  InsD108                                                                                N/A                                                                                      N/A                        N/A
  R112W                                                                                  1.96×10^3^ ± 2.82×10^2^                                                                  N/D                        N/D
  C149Y                                                                                  2.36×10^2^ ± 1.25×10^1^                                                                  N/D                        2.13×10^1^ ± 1.65
  Ddn and orthologs                                                                                                                                                                                          
  Ddn Mtb                                                                                8.49×10^4^ ± 9.32×10^3^                                                                  3.66×10^2^ ± 3.3×10^1^     1.03×10^2^ ± 7.59
  MMAR_5035                                                                              7.99×10^3^ ± 9.11×10^2^                                                                  2.3×10^2^ ± 1.44×10^1^     3.26×10^1^ ± 7.11
  MUL_4109                                                                               2.21×10^1^ ± 2.71                                                                        N/D                        N/D
  MVAN_5261                                                                              5.74×10^3^ ± 7.87×10^1^                                                                  N/D                        N/D
  MAV_0613                                                                               4.51×10^3^ ± 1.24×10^3^                                                                  N/D                        N/D
  MSMEG_5998                                                                             7.35×10^3^ ± 7.91×10^2^                                                                  N/D                        N/D
  Mutations based on naturally occurring sequence polymorphisms in *M*. *tuberculosis*                                                                                                                       
  P6S                                                                                    3.74×10^4^ ± 8.74×10^3^                                                                  3.29×10^2^ ± 1.63×10^1^    8.94×10^1^ ± 4.64
  P6T                                                                                    5.07×10^4^ ± 5.16×10^3^                                                                  5.07×10^2^ ± 3.18×10^1^    1.13×10^2^ ± 4.17
  P6L                                                                                    8.24×10^4^ ± 1.46×10^3^                                                                  1.94×10^2^ ± 2.84          5.84×10^1^ ± 1.23×10^1^
  M21T                                                                                   1.52×10^4^ ± 1.26×10^3^                                                                  3.65×10^2^ ± 8.99          7.29×10^1^ ± 3.60
  R23L                                                                                   4.59×10^4^ ± 3.28×10^3^                                                                  4.95×10^2^ ± 1.02×10^1^    1.20×10^2^ ± 3.93
  R23W                                                                                   9.86×10^4^ ± 9.98×10^3^                                                                  2.00×10^2^ ± 1.37×10^1^    9.15×10^1^ ± 3.25×10^1^
  T26P                                                                                   3.29×10^3^ ± 3.43×10^2^                                                                  6.21×10^1^ ± 9.18          5.82 ± 3.10
  W27C                                                                                   1.44×10^4^ ± 2.10×10^2^                                                                  1.66×10^2^ ± 5.98          4.19×10^1^ ± 1.91
  Y29H                                                                                   1.51×10^4^ ± 1.54×10^3^                                                                  5.11×10^1^ ± 7.60          1.77×10^1^ ± 4.81
  Y29S                                                                                   7.25×10^3^ ± 6.67×10^2^                                                                  3.88×10^1^ ± 9.51×10^−1^   7.15 ± 2.69
  R30S                                                                                   6.04×10^4^ ± 1.86×10^3^                                                                  1.44×10^2^ ± 1.81×10^1^    7.11×10^1^ ± 7.87
  G34E                                                                                   6.65×10^4^ ± 3.10×10^3^                                                                  7.39×10^1^ ± 4.72          5.29×10^1^ ± 6.98
  G34R                                                                                   9.14×10^3^ ± 7.79×10^2^                                                                  3.36×10^1^ ± 5.92          4.19×10^1^ ± 2.77
  G36V                                                                                   4.78×10^4^ ± 5.09×10^2^                                                                  8.16×10^1^ ± 1.36×10^1^    4.91×10^1^ ± 1.88
  P45L                                                                                   7.69×10^2^ ± 5.92×10^1^                                                                  8.29×10^1^ ± 1.52×10^1^    7.78×10^1^ ± 1.05
  L49P                                                                                   4.99×10^1^ ± 7.87                                                                        N/D                        N/D
  T50P                                                                                   3.36×10^2^ ± 6.07×10^1^                                                                  5.37×10^1^ ± 7.75          5.65×10^1^ ± 5.90
  T51P                                                                                   1.35×10^3^ ± 1×10^2^                                                                     3.70×10^1^ ± 4.80          2.87×10^1^ ± 5.04×10^−1^
  T52N                                                                                   7.61×10^4^ ± 1.01×10^4^                                                                  2.74×10^2^ ± 6.21          1.19×10^2^ ± 7.13
  T52P                                                                                   9.66×10^3^ ± 3.38×10^2^                                                                  8.73×10^1^ ± 6.03          5.07×10^1^ ± 3.04
  T56P                                                                                   1.20×10^4^ ± 2.84×10^3^                                                                  1.01×10^1^ ± 8.60×10^−1^   2.79×10^1^ ± 9.43×10^−1^
  G57A                                                                                   5.60×10^4^ ± 1.47×10^3^                                                                  2.65×10^2^ ± 1.32×10^1^    9.69×10^1^ ± 9.43
  V61G                                                                                   4.98×10^4^ ± 3.05×10^3^                                                                  1.01×10^2^ ± 2.25          5.46×10^1^ ± 6.00
  N62D                                                                                   1.22×10^3^ ± 1.62×10^2^                                                                  1.68×10^1^ ±9.60×10^−1^    2.19×10^1^ ± 1.80
  Y65S                                                                                   1.12×10^3^ ± 8.63×10^1^                                                                  N/D                        N/D
  L67P                                                                                   6.86×10^2^ ± 8.52                                                                        3.58×10^1^ ± 6.73×10^−1^   1.55×10^1^ ± 1
  D69N                                                                                   6.33×10^4^ ± 1.28×10^3^                                                                  2.94×10^2^ ± 4.06          1.25×10^2^ ± 2.00×10^1^
  G71R                                                                                   9.49×10^4^ ± 4.63×10^3^                                                                  3.71×10^2^ ± 6.81          1.31×10^2^ ± 1.86
  R72Q                                                                                   5.20×10^4^ ± 9.28×10^2^                                                                  2.11×10^2^ ± 1.14×10^1^    8.32×10^1^ ± 4.33
  R72W                                                                                   5.08×10^4^ ± 1.31×10^3^                                                                  2.27×10^2^ ± 1.47          1.07×10^2^ ± 1.99
  S78Y                                                                                   1.41×10^1^ ± 3.05                                                                        N/D                        1.21×10^1^ ± 2.72
  K79Q                                                                                   7.95×10^3^ ± 8.05×10^2^                                                                  N/D                        N/D
  G81S                                                                                   1.52×10^4^ ± 1.26×10^3^                                                                  3.00×10^1^ ± 5.93          2.28×10^1^ ± 2.81
  E83D                                                                                   6.93×10^4^ ± 3.28×10^3^                                                                  4.22×10^2^ ± 6.09×10^1^    1.56×10^2^ ± 1.04×10^1^
  W88R                                                                                   2.16×10^1^ ± 7.18×10^−2^                                                                 N/D                        N/D
  L90V                                                                                   6.61×10^4^ ± 2.60×10^3^                                                                  2.49×10^2^ ± 1.23×10^1^    7.68×10^1^ ± 8.40
  N91T                                                                                   2.24×10^3^ ± 5.07×10^2^                                                                  3.19×10^1^ ± 5.85          3.00×10^1^ ± 1.45
  I102V                                                                                  7.60×10^4^ ± 4.82×10^3^                                                                  2.88×10^2^ ± 1.10×10^1^    8.25×10^1^ ± 1.54×10^1^
  E105Q                                                                                  1.08×10^5^ ± 1.60×10^4^                                                                  3.49×10^2^ ± 7.56          1.23×10^2^ ± 1.78
  A111V                                                                                  5.62×10^2^ ± 2.25×10^1^                                                                  4.22×10^1^ ± 7.77          2.24×10^1^ ± 3.64
  D113N                                                                                  3.45×10^4^ ± 1.31×10^3^                                                                  1.94×10^2^ ± 1.26×10^1^    4.48×10^1^ ± 5.85
  E117K                                                                                  7.07×10^4^ ± 2.11×10^3^                                                                  3.13×10^2^ ± 5.83          9.15×10^1^ ± 8.51
  P124S                                                                                  7.18×10^4^ ± 2.48×10^3^                                                                  2.92×10^2^ ± 3.35          8.75×10^1^ ± 1.03×10^1^
  Y133C                                                                                  1.82×10^3^ ± 1.54×10^2^                                                                  N/D                        3.90 ± 1.95
  T140I                                                                                  7.28×10^4^ ± 4.09×10^2^                                                                  1.66×10^2^ ± 2.40×10^1^    1.03×10^2^ ± 3.50
  V147M                                                                                  4.38×10^4^ ± 4.29×10^3^                                                                  1.51×10^2^ ± 5.97          6.40×10^1^ ± 7.73
  Potential spontaneous mutations within the substrate binding site of Ddn                                                                                                                                   
  Y65L                                                                                   4.07×10^4^ ± 3.22×10^3^                                                                  N/D                        6.66×10^1^ ± 5.23
  Y65M                                                                                   6.72×10^4^ ± 5.78×10^3^                                                                  N/D                        2.25×10^1^ ± 2.82
  Y65S[\*](#t002fn002){ref-type="table-fn"}                                              1.12×10^3^ ± 8.63×10^1^                                                                  N/D                        N/D
  Y65C                                                                                   3.11×10^4^ ± 9.27×10^2^                                                                  N/D                        4.43×10^1^ ± 6.39
  Y65F                                                                                   3.59×10^4^ ± 2.09×10^3^                                                                  2.93×10^2^ ± 1.82×10^1^    2.41×10^2^ ± 1.35×10^1^
  S78A                                                                                   4.17×10^4^ ± 2.47×10^3^                                                                  N/D                        1.20×10^1^ ± 1.68
  S78C                                                                                   4.08×10^3^ ± 1.54×10^2^                                                                  N/D                        2.40×10^1^ ± 4.13
  S78T                                                                                   6.15×10^4^ ± 6.77×10^3^                                                                  N/D                        1.90×10^1^ ± 1.75
  S78V                                                                                   1.12×10^3^ ± 2.00×10^2^                                                                  N/D                        6.54 ± 3.87
  S78Y[\*](#t002fn002){ref-type="table-fn"}                                              1.41×10^1^ ± 3.05                                                                        N/D                        1.21×10^1^ ± 2.72
  Y130C                                                                                  3.31×10^3^ ± 3.92×10^2^                                                                  7.62×10^1^ ± 2.49          5.15×10^1^ ± 3.85
  Y130D                                                                                  7.08×10^3^ ± 2.17×10^3^                                                                  3.48×10^1^ ± 2.57          2.42×10^1^ ± 1.3
  Y130F                                                                                  1.41×10^4^ ± 2.12×10^3^                                                                  2.75×10^1^ ± 7.45          4.92×10^1^ ± 4.82×10^−1^
  Y130H                                                                                  4.63×10^3^ ± 4.05×10^2^                                                                  4.02×10^1^ ± 8.18          3.19×10^1^ ± 1.02×10^1^
  Y130N                                                                                  3.65×10^3^ ± 2.07×10^2^                                                                  7.66×10^1^ ± 8.82          3.57×10^1^ ± 4.03
  Y130S                                                                                  1.35×10^4^ ± 1.46×10^3^                                                                  2.19×10^2^ ± 2.24 ×10^1^   3.66×10^1^ ± 1.31×10^1^
  Y130W                                                                                  1.28×10^4^ ± 1.39×10^3^                                                                  9.77×10^1^ ± 2.57          5.53×10^1^ ± 4.63
  Y133C[\*](#t002fn002){ref-type="table-fn"}                                             1.82×10^3^ ± 1.54×10^2^                                                                  N/D                        3.90 ± 1.95
  Y133F                                                                                  4.08×10^4^ ± 3.03×10^3^                                                                  1.41×10^2^ ± 6.54          7.82×10^1^ ± 3.58
  Y133L                                                                                  8.87×10^4^ ± 1.10×10^3^                                                                  N/D                        2.78×10^1^ ±5.64
  Y133M                                                                                  5.82×10^4^ ± 3.57×10^3^                                                                  N/D                        1.64×10^1^ ± 2.32
  Y133W                                                                                  1.45×10^4^ ± 6.57×10^2^                                                                  N/D                        7.80 ± 4.47×10^−1^
  Y136E                                                                                  1.24×10^2^ ± 6.10                                                                        N/D                        4.51×10^1^ ± 1.93
  Y136T                                                                                  6.86×10^2^ ± 1.85×10^1^                                                                  N/D                        3.67 ± 1.17×10^−1^
  Y136F                                                                                  5.08×10^4^ ± 5.64×10^3^                                                                  3.88×10^2^ ± 3.07×10^1^    1.05×10^2^ ±1.29×10^1^
  Y136S                                                                                  5.13×10^2^ ± 1.38×10^1^                                                                  N/D                        N/D

N/D--Below limit of detection, N/A--Enzyme was unable to express,

\*---found in naturally occurring sequence polymorphisms

^a^--Data from this table is also used in [Table 3](#ppat.1008287.t003){ref-type="table"}, and Figs [4](#ppat.1008287.g004){ref-type="fig"} and [6](#ppat.1008287.g006){ref-type="fig"}

Having demonstrated that mutations can cause the loss of nitroimidazole-reducing activity *in vitro*, we investigated whether this corresponded to differences in nitroimidazole susceptibility *in vivo*. *M*. *tuberculosis* (H37Rv) and *M*. *marinum*, which were the only two species that encoded Ddn orthologs with in vitro pretomanid activation activity, were found to be susceptible to pretomanid and delamanid treatment ([Table 3](#ppat.1008287.t003){ref-type="table"}). In contrast, species in which the Ddn orthologs did not exhibit pretomanid activation activity (*M*. *smegmatis*, *M*. *ulcerans*, *M*. *avium*) have been shown to be naturally resistant to pretomanid \[[@ppat.1008287.ref005],[@ppat.1008287.ref032],[@ppat.1008287.ref033]\]. This analysis confims that the prodrug-activating activity of Ddn from *M*. *tuberculosis* H37Rv and *M*. *marinum* must result from sequence differences to the other Ddn orthologs tested.

10.1371/journal.ppat.1008287.t003

###### MICs of pretomanid and delamanid against different mycobacterial strains.

![](ppat.1008287.t003){#ppat.1008287.t003g}

                                                                                                             Pretomanid                                          Delamanid                                                                                        
  ---------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------------------------------- ---------------------------------------------------- -------------------------------------------
  *M*. *tuberculosis* H37Rv[^a^](#t003fn002){ref-type="table-fn"}                                            366 ± 33[^c^](#t003fn004){ref-type="table-fn"}      4                                           103 ± 7.59 [^c^](#t003fn004){ref-type="table-fn"}    32
  *M*. *tuberculosis* N0008[^a^](#t003fn002){ref-type="table-fn"}^,^[^b^](#t003fn003){ref-type="table-fn"}   N/D                                                 256                                         12.1 ± 2.72 [^c^](#t003fn004){ref-type="table-fn"}   32
  *M*. *marinum* M                                                                                           230 ± 14.4 [^c^](#t003fn004){ref-type="table-fn"}   16                                          326 ± 7.11 [^c^](#t003fn004){ref-type="table-fn"}    16
  *M*. *smegmatis* mc^2^155                                                                                  N/D                                                 \>50[\*](#t003fn005){ref-type="table-fn"}   N/D                                                  \>50[\*](#t003fn005){ref-type="table-fn"}

N/D--Below limit of detection

^a^MIC was determined by reazurin assay, measuring the minimal cell death concentration

^b^S78Y mutation

^c^Data used previously in [Table 2](#ppat.1008287.t002){ref-type="table"}, and Figs [4](#ppat.1008287.g004){ref-type="fig"} and [6](#ppat.1008287.g006){ref-type="fig"}

\*MICs obtained from Upton, A. et al. \[[@ppat.1008287.ref033]\]

Genome sequences of *M*. *tuberculosis* were then searched to identify nonsynonymous sequence polymorphisms within the *ddn* gene. We found that around 1.5% (219/14,876) of presumptive *M*. *tuberculosis* genomes screened encoded a non-synonymous mutation in *ddn*, including several that have arisen independently in unrelated strains ([S1 Table](#ppat.1008287.s002){ref-type="supplementary-material"}). Altogether, we identified 46 non-synonymous substitutions and 2 deletions in *ddn*, distributed throughout the *M*. *tuberculosis* phylogeny ([Table 4](#ppat.1008287.t004){ref-type="table"}).

10.1371/journal.ppat.1008287.t004

###### Distribution of Ddn alleles in the major *M*. *tuberculosis* lineages.

Distribution of Ddn alleles in five major lineages of *M*. *tuberculosis*.

![](ppat.1008287.t004){#ppat.1008287.t004g}

  Ddn allele     \#Strains   Lineage(s)
  -------------- ----------- -----------------------------------------------------------
  A111V          12          Lineage 4 (Euro American)
  D113N          7           Lineage 5 (West Africa)
  D69N           1           Lineage 4 (Euro American)
  E105Q          1           Lineage 4 (Euro American)
  E117K          1           Lineage 2 (East Asian-Beijing)
  E83D           4           Lineage 4 (Euro American)
  G34R           11          Lineage 4 (Euro American)
  G34E           2           Lineage 4 (Euro American)
  G36V           1           Lineage 1 (Indo-Oceanic)
  G57A           5           Lineage 1(Indo-Oceanic),Animal Lineage
  G71R           1           Lineage 4 (Euro American)
  G81S           9           Lineage 2 (East Asian-Beijing)
  I102V          1           Lineage 4 (Euro American)
  K79Q           1           Lineage 4 (Euro American)
  L49P           16          Lineage 2 (East Asian-Beijing)
  L67P           2           Lineage 4 (Euro American)
  L90V           1           Animal Lineage
  M21T           1           Lineage 3(East African-Indian)
  N62D           1           Lineage 4 (Euro American)
  N91T           1           Lineage 4 (Euro American)
  P124S          1           Lineage 2 (East Asian-Beijing)
  P45L           2           Lineage 4 (Euro American),Lineage 1 (Indo-Oceanic)
  P6L            2           Lineage 2 (East Asian-Beijing)
  P6S            9           Lineage 1 (Indo-Oceanic)
  P6T            2           Lineage 3(East African-Indian)
  P86_M87del     22          Lineage 4 (Euro American)
  R23L           1           Lineage 4 (Euro American)
  R23W           14          Lineage 4 (Euro American)
  R30S           3           Lineage 2 (East Asian-Beijing)
  R72Q           3           Lineage 4 (Euro American)
  R72W           34          Lineage 1 (Indo-Oceanic)
  S78Y           3           Lineage 2 (East Asian-Beijing)
  T140I          1           Lineage 4 (Euro American)
  T26P           2           Lineage 4 (Euro American)
  T50P           2           Lineage 2 (East Asian-Beijing)
  T51P           1           Lineage 2 (East Asian-Beijing)
  T52N           1           Lineage 2 (East Asian-Beijing)
  T52P           2           Lineage 3 (East African-Indian),Lineage 4 (Euro American)
  T56P           5           Lineage 4 (Euro American),Lineage 3 (East African-Indian)
  TTT50PPP       1           Lineage 3 (East African-Indian)
  V147M          1           Lineage 1 (Indo-Oceanic)
  V61G           5           Lineage 4 (Euro American)
  W27C           1           Lineage 2 (East Asian-Beijing)
  W88R           2           Lineage 4 (Euro American)
  Y122_M129del   5           Lineage 4 (Euro American)
  Y133C          1           Lineage 1 (Indo-Oceanic)
  Y29del         2           Lineage 2 (East Asian-Beijing)
  Y29H           1           Lineage 4 (Euro American)
  Y29S           2           Lineage 4 (Euro American)
  Y65S           3           Lineage 4 (Euro American)
  TG56PA         6           Lineage 3 (East African-Indian),Lineage 4 (Euro American)

All 46 mutants found in our genomic survey were expressed, purified, and assayed with menadione, pretomanid, and delamanid ([Table 2](#ppat.1008287.t002){ref-type="table"}, Figs [3](#ppat.1008287.g003){ref-type="fig"} and [4](#ppat.1008287.g004){ref-type="fig"}). Every mutant tested was able to reduce menadione, which is consistent with selective pressure for maintenance of the physiological function of Ddn. The majority of the mutants could also reduce/activate pretomanid and delamanid. This is not unexpected, as these *M*. *tuberculosis* strains have not (to our knowledge) been exposed to either drug and have therefore not been under selective pressure to develop resistance. However, of the 46 mutants, several mutants did not activate pretomanid (L49P, S78Y, K79Q, W88R, and Y133C) indicating that any strain of *M*. *tuberculosis* with these mutations would be unable to activate the drug. Indeed, an *M*. *tuberculosis* strain haboring the W88R mutation has been shown to be resistant to pretomanid *in vitro* \[[@ppat.1008287.ref020]\], and the L49P mutant was obtained from an *in vivo* resistance selection experiment \[[@ppat.1008287.ref034]\]. It is notable that the S78Y and Y133C mutants retained the ability to activate delamanid.

![Mutations to Ddn that were made in this study.\
The holo-enzyme structure of Ddn with a reconstructed N-terminus and F~420~ and pretomanid bound is shown, with mutations highlighted from mutants selected for pretomanid resistance in laboratory (orange spheres), non-synonymous mutations found in sequenced *M*. *tuberculosis* strains (green spheres), and potential spontaneous mutations within the substrate binding site of Ddn (blue spheres).](ppat.1008287.g003){#ppat.1008287.g003}

![Natural sequence polymorphisms found in *M*. *tuberculosis* stains.\
The activity of Ddn mutants with menadione, pretomanid, and delamanid. Bar color represents level of activity related to the rest of the graph with the highest activity colored red and the lowest activity colored blue. Error bars show standard deviations from three independent replicates. Data from this Figure is also present in Tables [2](#ppat.1008287.t002){ref-type="table"} and [3](#ppat.1008287.t003){ref-type="table"}.](ppat.1008287.g004){#ppat.1008287.g004}

The S78Y polymorphism is found in the genome of N0008 \[[@ppat.1008287.ref035]\], a clinical isolate of the hypervirulent Beijing family \[[@ppat.1008287.ref015]\], and in two other genomes (SRA accessions:ERR718320 and ERR751847) that are phylogenetically closely related, indicating a shared evolutionary history and suggesting that there was no substantial selective pressure to eliminate this mutation, i.e. its fitness cost must have been relatively small ([Fig 5](#ppat.1008287.g005){ref-type="fig"}). We obtained the Beijing strain N0008 to investigate whether the S78Y mutation in the *ddn* gene, which results in loss of pretomanid reduction *in vitro* ([Table 3](#ppat.1008287.t003){ref-type="table"}), corresponded to resistance to pretomanid *in vivo*. No other genetic changes previously observed to cause nitroimidazole resistance (e.g. loss of F~420~ biosynthetic genes) were apparent in the genome of N0008. We observed a 64-fold increase in minimum inhibitory concentration (MIC) of pretomanid against N0008 (256 μg mL^-1^) compared to H37Rv (4 μg mL^-1^). This suggests SNPs, such as L49P, S78Y and W88R, in the *ddn* gene can confer resistance to pretomanid and confirms that transmissible pretomanid-resistant populations of *M*. *tuberculosis* already exist.

![Phylogeny of *M*. *tuberculosis* strains with sequence polymorphisms in Ddn.\
Maximum-likelihood phylogenetic tree of 332 *M*. *tuberculosis* strains built using 2,099 non-recombinant core genome SNPs (relative to H37Rv). The tree shows all *M*. *tuberculosis* strains for which public genome data is available in Genbank or the short read archive (SRA) that have either synonymous and non-synonymous mutations in Ddn (relative to H37Rv). The amino acid changes of the non-synonymous mutations are indicated on the branch tips. Blank tips represent strains with synonymous mutations in Ddn. Branches are coloured by Lineage: Lineage 1 (Indo-Oceanic), yellow; Lineage 2 (East Asian-Beijing), red; Lineage 3 (East African-Indian), purple; Lineage 4 (Euro-American), green; Lineage 5 (West African), teal. The scale bar indicates branch length in number of SNPs. Genome alignments, recombination filtering and phylogenetic reconstruction were done using Parsnp, Gubbins and RaxML, respectively. The phylogenetic tree was visualised using Figtree version 1.4.3 (<https://tree.bio.ed.ac.uk/software/figtree>).](ppat.1008287.g005){#ppat.1008287.g005}

The potential for spontaneous pretomanid resistance mutations to arise in *M*. *tuberculosis* {#sec005}
---------------------------------------------------------------------------------------------

Previous studies have used laboratory evolution or engineering to investigate the potential for pathogens to evolve resistance to antibiotics \[[@ppat.1008287.ref036],[@ppat.1008287.ref037]\]. We took a similar approach here, using structure-guided mutagenesis to investigate the robustness of the nitroreductase activity of Ddn to mutations. The binding site of Ddn has been defined over several studies, identifying a number of polar amino acids within the substrate binding site that contribute to activity, particularly Y65, S78, Y130, Y133, Y136. Three of these binding site residues are fully conserved among the Ddn orthologs tested here, whereas Y65 and Y133 are more variable ([Fig 2c](#ppat.1008287.g002){ref-type="fig"}). We made, expressed and purified 26 mutants (including the Y65S, S78Y, and Y133C sequence differences observed some of the other Ddn orthologs) of these five key substrate binding residues (Y65, S78, Y130, Y133, Y136) ([Fig 3](#ppat.1008287.g003){ref-type="fig"}), to test how spontaneous mutations at these positions affect nitroimidazole activation. Across the 26 mutants tested, all retained significant levels of the native activity, while 16 did not display detectable pretomanid activation ([Table 2](#ppat.1008287.t002){ref-type="table"}, [Fig 6](#ppat.1008287.g006){ref-type="fig"}). In other words, while the native activity was not greatly affected by sequence variation, the promiscuous nitroreductase activity was extremely sensitive to mutation.

![Kinetic activities of mutants with potential spontaneous mutations within the substrate binding site of Ddn.\
The activity of Ddn mutants with menadione, pretomanid, and delamanid. Bar color represents level of activity related to the rest of the graph with the highest activity colored red and the lowest activity colored blue. Error bars show standard deviations from three independent replicates. Data from this Figure is also present in Tables [2](#ppat.1008287.t002){ref-type="table"} and [3](#ppat.1008287.t003){ref-type="table"}.](ppat.1008287.g006){#ppat.1008287.g006}

To estimate the rate at which mutations could spontaneously arise at one of the positions identified in this work, we used our genomic survey of *ddn* in *M*. *tuberculosis* to estimate the level of sequence variation in *ddn*. This revealed that virtually every distinct lineage of *M*. *tuberculosis* contains SNPs in *ddn*; given the burden of TB in the world and the potential for widespread pretomanid administration, alongside the apparent sensitivity of the promiscuous pretomanid activation activity to such SNPs in contrast to the native activity, it appears that spontaneous resistance enabling mutations of *ddn* could readily occur and spread with sufficient selective pressure.

The molecular basis of resistance {#sec006}
---------------------------------

The effects of the mutations shown in [Table 2](#ppat.1008287.t002){ref-type="table"} are generally consistent with our mechanistic understanding of Ddn from mutagenesis and computational simulation \[[@ppat.1008287.ref007],[@ppat.1008287.ref038]\]. For example, S78 is thought to interact with the nitro-moiety of pretomanid and to stabilize the transition state; none of the S78 mutants retained pretomanid nitroreductase activity, suggesting this interaction is particularly important. Y65, Y130, Y133 and Y136 are known to form a hydrophobic wall in the binding site, which can move during the catalytic cycle to shield the active site from solvent and thereby facilitate pretomanid reduction \[[@ppat.1008287.ref038]\]. This is in keeping with the observation that tyrosine to phenylalanine mutations at positions 65, 133 and 136 were essentially neutral, whereas substitution with other residues (Met, Leu, Cys, Trp, Thr, Ser, Glu) led to loss of pretomanid activation. Menadione reduction by Ddn is less susceptible to loss of activity through mutation, which is consistent with work showing native activities are substantially more robust to mutation than promiscuous activities (such as pretomanid activation) \[[@ppat.1008287.ref039]\], as well as the observation that menadione is more chemically labile.

Delamanid activation is less susceptible to resistance mutations {#sec007}
----------------------------------------------------------------

Of the 75 mutants we made and tested, 25 did not reduce pretomanid at detectable levels but only 10 lost the ability to reduce delamanid. Thus, although pretomanid and delamanid are superficially similar, they must interact with Ddn differently. These enzymatic data extend to whole cell activity, as we observed that the N0008 strain harbouring the S78Y mutation was resistant to pretomanid but remained susceptible to delamanid ([Table 3](#ppat.1008287.t003){ref-type="table"}). To better understand the molecular basis for the differential effects of mutations on pretomanid and delamanid activation, we used molecular docking (we were unable to capture ternary crystal structures with ligand and cofactor) to obtain low-energy poses of these substrates in the crystal structure of Ddn. The binding of delamanid is predicted to be different than that of pretomanid ([Fig 7B and 7C](#ppat.1008287.g007){ref-type="fig"}), with the dual methyl and phenoxy-methyl substituents on the oxazole ring preventing delamanid binding above the deazaflavin ring of F~420~ in a ring-stacked orientation, as is seen in pretomanid, which has an oxazine ring with a single substituent in the analogous position. This results in a change in the angle at which the nitroimidazole group interacts with the cofactor that results in an increase in the distance to S78Y. Thus, there appears to be a plausible molecular basis for the differing effects of the S78Y mutation on pretomanid and delamanid activity *in vitro* and *in vivo*.

![The substrate-binding pocket of Ddn (PDB: 3R5R).\
**(a)** Menadione (docking score = -6.584 kJ/mol) binds above the deazaflavin ring of F~420~H~2~ in a complementary pocket formed by the aromatic rings of the tyrosine residues and the hydroxyl group of Ser78. **(b)** Pretomanid (docking score = -5.995 kJ/mol) docked into wild-type Ddn with F~420~H~2~ bound. The nitroimidazo-oxazine moiety can bind parallel to the deazaflavin group of F~420~, extending the nitro-group deep into the active site, towards Ser78. **(c)** Delamanid (docking score = -4.890 kJ/mol) docked into wild-type Ddn with F~420~H~2~ bound. The dual methyl/phenoxy-methyl substitution at the C6 position of the oxazole ring creates steric hindrance with the deazaflavin ring of F~420~, causing it to bind above F~420~ in a perpendicular orientation. This results in additional distance to Ser78.](ppat.1008287.g007){#ppat.1008287.g007}

Ddn mutants are virulent in mice but show defective recovery from hypoxic stress *in vitro* {#sec008}
-------------------------------------------------------------------------------------------

To understand the fitness costs of loss of Ddn activity through mutation, we investigated the *in vitro* enzymatic properties of Ddn variants that have been identified in *M*. *tuberculosis*. Several isogenic pretomanid-resistant *M*. *tuberculosis* mutants have recently been selected by pretomanid monotherapy in infected mice and shown to harbour mutations in Ddn (M1T, L49P, L64P, R112W, C149Y and from insertion of the IS6110 transposable element at D108) \[[@ppat.1008287.ref034]\]. We also investigated two mutants from a previous study in which resistant strains were identified from an *in vitro* selection experiment (S22L, W88R). We tested the ability of these eight mutants to reduce native (menadione) and drug (pretomanid and delamanid) substrates *in vitro*, finding that all mutations resulted in loss of detectable pretomanid activation, consistent with their selection in resistant strains. We observed that the M1T mutant (loss of start codon) and the mutants harbouring the IS6110 insertions did not produce any functional protein and therefore had no detectable native, nor prodrug-activating activity. In contrast, many of the point mutants, such as the L64P mutant, retained a small amount of activity with menadione, suggesting that it might retain a fraction of its native function ([Table 2](#ppat.1008287.t002){ref-type="table"}). Because many of these mutants were found in *M*. *tuberculosis* living in mouse lungs, the fitness cost of these mutations is clearly low enough to allow them to survive in that environment.

To understand the fitness costs of loss of Ddn activity in more detail, we investigated the ability of *M*. *tuberculosis* strains with mutations in Ddn to survive in different conditions. We therefore tested a selection of variants: wild-type H37Rv (full native activity), L64P (partial loss of native activity), as well as M1T and IS6110 (complete loss of native activity) to examine whether these mutants were attenuated for multiplication and survival in mice. These mutants showed no difference in growth or survival compared to wild type after low-dose aerosol infection of mice ([Fig 8a](#ppat.1008287.g008){ref-type="fig"}), suggesting that these Ddn mutants would be transmissible.

![Fitness analysis of Ddn mutants.\
**(a)** *M*. *tuberculosis* Ddn mutants are not attenuated in mice. Mean lung colony-forming unit (CFU) counts of the H37Rv strain and isogenic Ddn mutants are shown following low-dose aerosol infection. Error bars represent SEM biological triplicate. Competition of the Δ*ddn* mutant compared to isogenic wild type mc^2^ 6230. (b) Growth and survival of the Δ*ddn* mutant compared to isogenic wild type in aerobic conditions. (c) Growth and survival of the Δ*ddn* mutant compared to isogenic wild type in hypoxic conditions. (A and B) Arrows indicate samples taken for competition assay. (d) Percentage of the Δ*ddn* mutant when grown in competition with the isogenic wild type. Two-way ANOVA with Tukey multiple comparisons test where \*, p\<0.05; \*\*, p\<0.01. Red \* is comparison between aerobic (Day 7) and Hypoxic (Day 37) at given timepoint, Black \* is comparison between aerobic (Day 7) and Hypoxic (Day 70) at given timepoint. Error bars for b, c and d representative of standard deviation biological triplicate.](ppat.1008287.g008){#ppat.1008287.g008}

A previous study showed that *M*. *tuberculosis* mutants that were unable to biosynthesise F~420~ have a survival defect when recovering from hypoxia \[[@ppat.1008287.ref012]\]. To better understand the competitive cost that loss of Ddn function causes to *M*. *tuberculosis* during recovery from hypoxia, we created a hygromycin marked deletion mutant in the mc^2^6230 strain of *Mycobacterium tuberculosis* using phage transduction. The suspected Δ*ddn* mutants with hygromycin resistance displayed MIC values against delamanid of greater than 512 μM. The deletion mutants were then confirmed using whole genome sequencing ([S1 Fig](#ppat.1008287.s001){ref-type="supplementary-material"}). The Δ*ddn* mutant displayed no growth or survival defects compared to the isogenic wild type when grown in aerobic or hypoxic conditions ([Fig 8b and 8c](#ppat.1008287.g008){ref-type="fig"}) consistent with the previous results on *ddn* point mutants ([Fig 8a](#ppat.1008287.g008){ref-type="fig"}). We then tested the marked Δ*ddn* strain in competition with the wild type isogenic strain when reaerated from hypoxia. As a control we took the day 7 aerobic growth sample of each strain and grew them in competition. We found that the Δ*ddn* mutant had lost no competitiveness when taken from aerobic conditions with the proportional percentage of Δ*ddn* remaining at about \~50% ([Fig 8d](#ppat.1008287.g008){ref-type="fig"}). We then took equal proportions of each strain from hypoxia at 37 days and 70 days, which we grew in competition ([Fig 8c](#ppat.1008287.g008){ref-type="fig"}). The proportion of Δ*ddn* was then measured at days 0, 7 and 17. We found that with the Day 37 hypoxic sample the Δ*ddn* mutant had an initial drop in proportion to 28% at 7 days but by day 17 the proportion of the Δ*ddn* mutant had returned to 57% ([Fig 8d](#ppat.1008287.g008){ref-type="fig"}). The day 70 hypoxic sample had an initial drop off Δ*ddn* proportion to 33% which was maintained through until day 17 ([Fig 8d](#ppat.1008287.g008){ref-type="fig"}). These data demonstrate that the Δ*ddn* mutant cannot compete with wild type after exit from prolonged hypoxia and that Ddn contributes to fitness under these conditions, perhaps because they are more susceptible to oxidative stress or have some defect in respiration.

Discussion {#sec009}
==========

The fitness trade-off between resistance and native function {#sec010}
------------------------------------------------------------

Given the conservation of Ddn-like genes throughout mycobacteria, its activity with menaquinone, and the inability of Ddn knock-outs to recover from hypoxia, we suggest that mutations that completely knock-out Ddn activity (including the loss of F~420~ biosynthesis through mutations to F~420~ biosynthetic genes, loss of F~420~ reductase activity through knockout of FGD, and introduction of stop codons or large genetic insertions/deletions in *ddn*) could result in substantial loss of fitness given that the ability to recover from hypoxia is an important aspect of *M*. *tuberculosis* pathogenesis \[[@ppat.1008287.ref003],[@ppat.1008287.ref023],[@ppat.1008287.ref040]--[@ppat.1008287.ref042]\]. Thus, for nitroimidazole resistance to spread and endanger health, the activity of Ddn must be either retained or otherwise compensated for. This means that mutations that are neutral or near-neutral for the wild-type activity, but knock out nitroimidazole-activation, will be of great clinical concern.

The binding of the prodrugs pretomanid and delamanid by Ddn, which leads to the activation of these prodrugs, is a promiscuous activity that is not fully coupled to its ability to bind and reduce its native substrate; i.e. loss of pretomanid activation is possible without total loss of the native activity. It has long been known that promiscuous activities of enzymes are less robust to the effects of mutations than native enzyme functions \[[@ppat.1008287.ref039]\], meaning that it is possible that mutations could cause loss of prodrug activation without significant loss of native function. In this study we tested this assumption for Ddn, mutating \~1/3 of the amino acid positions in *M*. *tuberculosis* Ddn, including all known naturally occurring polymorphisms, showing that many such mutations (including several already present in clinical isolates) can cause loss of delamanid and/or pretomanid activation without loss of the native activity. Extending our enzymatic measurements to measurement of MICs revealed that related species with sequence differences in *ddn*, and clinical isolates of *M*. *tuberculosis* that harbor mutations within the active site, are resistant to pretomanid. These results have important implications for the clinical use of nitroimidazoles in TB treatment in order to optimize treatment outcomes and to prevent or slow the development of resistance. For instance, pretomanid will not be effective in patients infected with naturally occurring *M*. *tuberculosis* variants harbouring an S78Y mutation and indiscriminant use of pretomanid against such variants (such as in regions in which the N0008 strain is endemic) could drive selective amplification and spread of pretomanid resistance. Moreover, the chances of spontaneous mutation of Ddn in currently sensitive strains is significant, given our observation of the number of single nucleotide mutations that can knock out nitroreductase activity. Given that the clinical isolate N0008 is highly transmissible, it is likely that other Ddn variants in which nitroreductase activity can be abolished without substantial loss of the native activity will also be infectious owing to the minimal loss of fitness these mutations cause with the native activity. Thus, fitness-neutral Ddn mutations are likely to be a prominent route through which clinical pretomanid and delamanid resistance spreads.

Our findings have broad implications for the continued clinical development and usage of nitroimidazole antitubercular agents. Through multiple ongoing phase II/III clinical trials, the TB Alliance and others are evaluating novel combination therapies including pretomanid. The ongoing ZeNix and TB-PRACTECAL trials are extending the study of the BPaL (bedaquiline, pretomanid, linezolid) regimen that showed highly promising results against MDR- and XDR-TB in the Nix-TB trial, while the SimpliciTB trial studies the BPaMZ regimen (bedaquiline, pretomanid, moxifloxacin, pyrazinamide) against MDR- and drug-susceptible TB. Meanwhile, comparable delamanid-containing regimens are being studied in the endTB and MDR-END trials. Now that both delamanid and pretomanid are approved for clinical use, intensive monitoring of *ddn* polymorphisms is recommended to ensure informed regimen selection and allow interventions that will reduce spreading of transmissible resistance. Our findings indicate that delamanid binds to Ddn in a different conformation than pretomanid does, suggesting that it could be effective against some pretomanid-resistant isolates. It is also possible that combination therapy with both nitroimidazoles could help prevent the evolution and spread of resistance (since the simultaneous loss of both activities will be less likely to result from single amino acid substitution). Further studies on how delamanid and pretomanid are activated in the *M*. *tuberculosis* cell will inform the development of improved nitroimidazole therapies and testing of a broad range of nitroimidazole analogs against a panel of Ddn variants could help to identify compounds for which resistance is less likely to evolve.

Materials and methods {#sec011}
=====================

Plasmid construction and point mutation {#sec012}
---------------------------------------

The *E*. *coli* codon optimised sequences for Ddn from *M*. *tuberculosis*, MSMEG_5998 from *M*. *smegmatis*, MMAR_5035 from *M*. *marinum*, MVAN_5261 from *M*. *vanbaalenii*, MAV_0613 from *M*. *avium*, and MUL_4109 from *M*. *ulcerans* were purchased as gene strings from ThermoFisher Scientific (Massachusetts, USA) and cloned into the expression vector pMAL-c2X using Gibson assembly \[[@ppat.1008287.ref043]\]. All mutations to Ddn were made by site-directed mutagenesis using Gibson assembly \[[@ppat.1008287.ref043]\]. Construction of MSMEG_2027 and FGD has been described previously \[[@ppat.1008287.ref044],[@ppat.1008287.ref045]\].

Protein expression and purification {#sec013}
-----------------------------------

MSMEG_2027 was expressed and purified as previously described \[[@ppat.1008287.ref013]\]. Ddn, Ddn mutants, and Ddn orthologs were transformed into *E*. *coli* BL21 (DE3) cells and grown on LB agar containing 100 μg/ml ampicillin. Single colonies were picked and inoculated in LB media with 100 μg/ml ampicillin. Starter cultures were grown overnight and diluted 1/100 and grown at 37 °C until OD = 0.4. Cultures were induced with IPTG to a final concentration of 0.3 mM, and grown for 3 h at 25 °C. Cells were harvested by centrifugation at 8,500 × *g* for 20 minutes at 4 °C and resuspended in lysis buffer (20 mM Tris-Cl, pH 7.5, 200 mM NaCl) and lysed by sonication using an Omni Sonicator Ruptor 400 (2 x 6 min. at 50% power). The soluble extract was obtained by centrifugation at 13,500 × *g* for 1 h at 4 °C. The protein was purified using amylose resin (NEB) using the provided protocol. Briefly the lysate was passed over the amylose resin and washed with 12 column volumes of lysis buffer. The protein was eluted using elution buffer (same as lysis buffer but with 10 mM maltose). Samples were frozen at -80 °C in 20 mM tris pH 7.5, 200 mM NaCl, 10 mM maltose, and 10% glycerol.

FGD was expressed and purified as described by Bashiri *et al*. \[[@ppat.1008287.ref045]\], with minor modifications. FGD was transformed into *E*. *coli* BL21 (DE3) cells and grown on LB agar containing 100 μg/ml ampicillin. Single colonies were picked and inoculated in Terrific Broth (TB) \[[@ppat.1008287.ref046]\] with 100 μg/ml. ampicillin. Starter cultures were grown overnight and diluted 1/100 into auto-induction media (20 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl, 6 g/l Na~2~HPO~4~, 3 g/l KH~2~PO~4~, 6 ml/l glycerol, 2 g/l lactose, 0.5 g/l glucose, 100 mg/ml ampicillin) and grown at 30 °C for 24 h. The cells were harvested by centrifugation at 8500 g for 20 min at 4 °C and resuspended in lysis buffer (20 mM NaPO~4~ pH 8, 300 mM NaCl, 25 mM imidazole) and lysed by sonication using an Omni Sonicator Ruptor 400 (2 x 6 min at 50% power). The soluble extract was obtained by centrifugation at 13500 g for 1 h at 4 °C. The soluble fraction was filtered and loaded 5-ml HisTrap HP column (GE Healthcare) and washed with lysis buffer. The protein was eluted with elution buffer (lysis buffer with 250 mM imidazole). The purified protein was dialyzed in 50 mM Tris-Cl, pH 7, 200 mM ammonium sulphate. Samples were frozen at -80 °C in 50 mM Tris-Cl, pH 7, 200 mM ammonium sulphate, and 10% glycerol.

Enzymatic assays {#sec014}
----------------

F~420~ was purified from M. *smegmatis* mc^2^4517 as described by Ahmed *et al*.\[[@ppat.1008287.ref013]\]. F~420~ was reduced overnight with 10 μM FGD and 10 mM glucose-6-phosphate in 20 mM Tris-CL, pH 7.5 under anaerobic conditions. FGD was removed by spin filtration in a 1 mL 10 K MWCO spin filter (Millipore) and used F~420~H~2~ within 8 hours. Enzyme assays were performed according to Ahmed *et al*. \[[@ppat.1008287.ref013],[@ppat.1008287.ref047]\] in 200 mM Tris-HCl, pH 7.5, 0.1% Triton X-100, 25 μM F~420~H~2~, and 25 μM of substrate at room temperature. Enzyme concentrations used were between 0.1 μM and 1 μM. Activity was monitored following the oxidation of F~420~H~2~ which was measured spectrophotometrically at 420 nm (ε = 41,400 M^−1^ cm^−1^) \[[@ppat.1008287.ref048]\]. Specific enzymatic activity with delamanid was measured using fluorescence (excitation/emission: 400 nm/470 nm).

Computational analysis {#sec015}
----------------------

Sequences of Ddn and orthologs were obtained from the NCBI sequence database. Alignment of the sequences were performed using MUSCLE \[[@ppat.1008287.ref049]\] via the EMBL-EBI web services \[[@ppat.1008287.ref050]\]. Autodock Vina \[[@ppat.1008287.ref051]\] was used to dock menadione, pretomanid and delamanid into Ddn (PDB ID: 3R5R) \[[@ppat.1008287.ref007]\]). The protein and ligand were prepared using in Autodock tools with default settings \[[@ppat.1008287.ref052]\] and visualized using Pymol \[[@ppat.1008287.ref053]\]. Substrate structures were obtained from the ZINC database \[[@ppat.1008287.ref054]\].

Drug susceptibility testing {#sec016}
---------------------------

Minimum inhibitory concentration (MIC) testing of *M*. *marinum* was performed according to the method of Wiegand *et al*. \[[@ppat.1008287.ref055]\] with some minor modifications. A culture was grown on Brown and Buckle media and colonies were scraped and diluted to an OD~600~ of 0.2, and was used as the inoculum for the MIC assay. Plates were incubated at 30 °C in a humid environment and were read after 5 days of incubation. MICs of *M*. *tuberculosis* isolates were determined as described previously \[[@ppat.1008287.ref056]\] with slight modifications. Briefly, U-bottomed 96-well microtitre plates containing Middlebrook 7H9 broth supplemented with oleic acid, albumin, dextrose and catalase were inoculated with *M*. *tuberculosis* H37Rv or N0008 (OD~600~ 0.02) in the presence of delamanid and pretomanid (0.015--512 μg/ml), and incubated at 37 °C for 5 days. The presence/absence of a cell pellet was checked visually. Resazurin (0.03% w/v) was then added, and plates were further incubated for 7 days. Viable cells reduce resazurin (blue) to resorufin (pink). Bedaquiline (0.015--32 μg/ml) was used as a drug susceptibility control.

Dataset {#sec017}
-------

To determine the frequency of non-synonymous sequence polymorphisms in the *ddn* gene we assembled a collection of 5,184 publicly available complete and draft *M*. *tuberculosis* genomes from Genbank \[[@ppat.1008287.ref057]\] on the 7^th^ of April 2017. Additionally, using the structured query [https://www.ncbi.nlm.nih.gov/sra/(Illumina\[Platform\])](https://www.ncbi.nlm.nih.gov/sra/(Illumina[Platform])) AND "Mycobacterium tuberculosis"\[orgn:\_\_txid1773\]) to search the SRA (<https://www.ncbi.nlm.nih.gov/sra/>) opened on the 28^th^ of April 2017, we identified 9,692 unassembled *M*. *tuberculosis* genome datasets.

Lineage-typing of *M*. *tuberculosis* genomes {#sec018}
---------------------------------------------

Classification of *M*. *tuberculosis* phylogenetic lineages was performed using KvarQ version 0.12.3a1 and default parameters \[[@ppat.1008287.ref058]\]. Using KvarQ scan, unassembled sequencing data were screened against a database of previously defined sequence polymorphisms known to delineate the 7 major *M*. *tuberculosis* phylogenetic lineages ([S1 Table](#ppat.1008287.s002){ref-type="supplementary-material"}).

Characterisation of *ddn* sequence polymorphisms in *M*. *tuberculosis* {#sec019}
-----------------------------------------------------------------------

Using BLASTn (with default parameters) complete and draft *M*. *tuberculosis* genome assemblies from Genbank were queried with the *ddn* gene from *M*. *tuberculosis* H37Rv (Genbank accession:AL123456; \[[@ppat.1008287.ref059]\]), identifying 145 *M*. *tuberculosis* genomes carrying alternative *ddn* alleles (relative to H37Rv). For these 145 genomes the Ddn sequence was extracted and aligned using Clustal Omega version 1.2.4 \[[@ppat.1008287.ref060]\] to identify non-synonymous mutation and other sequence polymorphism which could impact the function of Ddn ([S1 Table](#ppat.1008287.s002){ref-type="supplementary-material"}).

For the unassembled genomes datasets, raw sequencing reads were aligned to the reference genome *M*. *tuberculosis* H37Rv using Snippy version 2.9 (BWA-mem version 0.7.12 \[[@ppat.1008287.ref061]\])(<https://github.com/tseeman/snippy>). Variant calling was performed using Snippy (Freebayes version 0.9.21 \[[@ppat.1008287.ref062]\] with default parameters (minimum read coverage of 10x and 90% read concordance at the variant locus). 244 unassembled genome datasets were identified as having a mutation in *ddn*, only three of which were represented amongst the afore-mentioned 145 assembled genomes available in GenBank.

Taxonomic profiling of unassembled sequencing data {#sec020}
--------------------------------------------------

Kraken \[[@ppat.1008287.ref063]\], an ultrafast sequence classification tool, was used to assign taxonomic labels to the unassembled *M*. *tuberculosis* genomes from the SRA. Sequence reads for each genome from the SRA were screened against a NCBI refseq database (<https://www.ncbi.nlm.nih.gov/refseq>) using Kraken version 0.10.5 to identify contaminants. Of the 244 *M*. *tuberculosis* genomes with sequence polymorphisms in *ddn*, 67 (27.5%) were found to be contaminated with DNA from unidentified organisms or from *Mycobacterium* species other than *M*. *tuberculosis* ([S2 Table](#ppat.1008287.s003){ref-type="supplementary-material"}). These genomes were excluded from all further analysis.

Phylogenetic reconstruction of *M*. *tuberculosis* strains with sequencing polymorphisms in Ddn {#sec021}
-----------------------------------------------------------------------------------------------

To determine the phylogenetic distribution of *ddn* alleles in *M*. *tuberculosis* we carried out a phylogenomic analysis of *M*. *tuberculosis* strains with sequence polymorphism in *ddn*. Firstly, unassembled genomes from the SRA were assembled *de novo* using SPAdes version 3.9.0 \[[@ppat.1008287.ref064]\]. Next, all 322 complete and draft genomes ([S3 Table](#ppat.1008287.s004){ref-type="supplementary-material"}) were aligned with Parsnp version 1.2 \[[@ppat.1008287.ref065]\] using the genome of H37Rv as a reference to produce a core genome alignment of 848,476 bp. Core genome SNPs were identified and recombinant regions removed using Gubbins version 2.2.0 \[[@ppat.1008287.ref066]\]. Finally, a maximum-likelihood phylogenetic tree was estimated using RAxML version 8.2.9 \[[@ppat.1008287.ref067]\] under the GTRGAMMA nucleotide substitution model.

Evaluation of *ddn* mutant fitness in low-dose aerosol mouse infection model {#sec022}
----------------------------------------------------------------------------

Isogenic pretomanid-resistant mutants were selected in the *M*. *tuberculosis* H37Rv strain background and subjected to whole genome sequencing, as previously described \[[@ppat.1008287.ref034]\]. In the present study, female BALB/c mice were aerosol-infected with the H37Rv parent strain or one of the following isogenic *ddn* mutants, implanting approximately 2 log~10~ CFU/lung in each case: L64P, M1T, or IS6110 insertion at D108. Three mice from each group were sacrificed on the day after infection to confirm the number of CFU implanted. The multiplication and persistence of each strain was evaluated by sacrificing 3 mice/group and quantifying the CFU counts by plating serial dilutions of lung homogenate on Middlebrook selective 7H11 agar at 2, 4, 8, 13 and 23 weeks post-infection.

Evaluation of *ddn* mutant fitness during and after hypoxic stress {#sec023}
------------------------------------------------------------------

The H37Rv parent and isogenic *ddn* mutants used for mouse infection were inoculated into tubes containing Dubos Tween Albumin Broth (BD Difco) supplemented with the hypoxia indicator dye, methylene blue (500 μg/ml). Tubes were sealed with rubber stoppers and incubated at 37 °C with slow magnetic stirring. The reduction and decolorization of methylene blue served as a visual indicator of oxygen levels corresponding to NRP stage 2 \[[@ppat.1008287.ref068],[@ppat.1008287.ref069]\], which was attained in all cultures by day 24. Aliquots were removed for quantitative culture on 7H11 agar after 15, 24, 29, 43 and 57 days of incubation. Samples were collected by piercing the rubber stoppers with a syringe and sampling did not introduce atmospheric oxygen into the tubes, as shown by maintenance of the decolorized dye state. After day 57, each strain was returned to normoxic conditions by transferring the contents of the tubes to sterile Erlenmeyer flasks and incubated at 37 °C in a shaker for another 14 days \[[@ppat.1008287.ref070]\]. Aliquots were removed for quantitative culture after 7 and 14 days of normoxia.

DDN marked deletion construction {#sec024}
--------------------------------

To generate the DDN Hygromycin marked deletion mutant we used a high throughput phage-based method based on Jain et al (2014) \[[@ppat.1008287.ref071]\]. The phasmid construct for this deletion was a gift from William R. Jacobs. The DDN deletion phasmid DNA was electroporated into electrocompetent *M*. *smegmatis*. The *M*. *smegmatis* was recovered for two hours in 7H9, then split and mixed into two 7H9 agar overlay mixtures (7H9 powder + 0.3% agar) and spread on 7H11 plates. The plates were incubated for two to three days at 30°C to allow phage growth and lysis. Resulting plaques were picked using a pasteur pipette and resuspended in MP buffer (50 mM Tris, 150 mM NaCl, 10 mM MgSO4, 2 mM CaCl2, pH 7.6--7.8). The MP buffer containing the phage was split and mixed with two *M*. *smegmatis* cultures, followed by mixing into two 7H9 agar overlay mixtures. The overlay mixes were spread on 7H11 plates and examined for plaques after two to three days at 30°C. This resulted in an increased number of plaques, which were harvested by pipetting MP buffer on the of the plate and shaking at 100 rpm for 3 hours. The MP buffer containing the phage was harvested from the plate with a syringe before being passed through a 20 μm filter to remove the bacteria. The resulting sterile MP buffer with phage titre was quantified by serial dilution followed by spot plating onto dry *M*. *smegmatis* overlay plates. The phage amplification was repeated until a titre of 10^9^, 10^10^ phage was achieved. mc^2^ 6230 *Mycobacterium tuberculosis* was grown up in ink wells to an optical density (600 nm) of 0.6 to 0.8, before harvest at 3,126 x g. Cells were then transduced by resuspension in the MP buffer containing the phage titre at 37 °C (to prevent phage lysing the cell) overnight followed by plating on 7H11 with 50 μg/mL hygromycin. Colonies with hygromycin resistance were indicative of successful double homologous recombination with the gene being replaced with hygR-*sacB* DNA fragment. The Δ*ddn* mutant was screened for resistance to delamanid. The Δ*ddn* mutant was confirmed through whole genome sequencing (Illumina 150 bp paired end reads) with reads mapped using the Bowtie2 plugin for Geneious to the wild type H37RV genome ([S1a Fig](#ppat.1008287.s001){ref-type="supplementary-material"}) and a H37RV genome with the expected hygromycin marker ([S1b Fig](#ppat.1008287.s001){ref-type="supplementary-material"}).

Competition assays {#sec025}
------------------

For the competition assay aerobically grown cultures the Δ*ddn* mutant and wild type mc^2^ 6230 were grown in 7H9 in separate inkwells and monitored by spot platting 5 μL of a serial dilution in triplicate on 7H11 agar plates. At 7 days a new combined inkwell was inoculated with 100μL of each strain. For the competition assay from hypoxically grown cultures the Δ*ddn* mutant and wild type mc^2^ 6230 were grown in separate 30 mL serum vials in 7H9 and monitored by spot platting 5 μL of a serial dilution in triplicate on 7H11 agar plates. Oxygen depletion was estimated by de-colourisation of 1.5 μg/mL methylene blue which occurred between 17--27 days. At 37 days 100 μL of the Δ*ddn* mutant and wild type mc^2^ 6230 was taken and used to inoculate a single inkwell with 10 mL 7H9. At 70 days 200 μL of the Δ*ddn* mutant and wild type mc^2^ 6230 was taken and used to inoculate a single inkwell with 10 mL 7H9. The combined inkwells with both strains were assayed for the proportion of the Δ*ddn* mutant by spot platting 5 μL of a serial dilution in triplicate on 7H11 agar plates with and without 50 μg/mL hygromycin. The Δ*ddn* mutant proportion of total cells was established from the number of colonies on the hygromycin agar plates and expressed as a percentage of total colonies on the plates with no hygromycin.

Supporting information {#sec026}
======================

###### 

\(A\) Map of the Δ*ddn* mutant reads using Bowtie 2 to H37Rv genome. (B) Map of the Δ*ddn* mutant reads using Bowtie 2 to H37Rv genome with expected hygromycin marker.

(TIF)

###### 

Click here for additional data file.

###### Distribution of Ddn alleles in the major TB lineages.

(XLSX)

###### 

Click here for additional data file.

###### Taxonomic classification of sequence reads from bacterial genome data sets described as M. tuberculosis on the sequence read archive (SRA) using Kraken: Red shading indicates genome datasets contaminated with DNA from unknown organisms (Reads classified (%)) or datasets where the majority of reads, identified as genus Mycobacterium, match to a Mycobacterium species other than M. tuberculosis.

(XLSX)

###### 

Click here for additional data file.

###### *M*. *tuberculosis* genome datasets used in this study.

(XLSX)

###### 

Click here for additional data file.
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Dear Mr Lee,

Thank you very much for submitting your manuscript \"Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering\" (PPATHOGENS-D-19-01241) for review by PLOS Pathogens. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the manuscript as it currently stands. These issues must be addressed before we would be willing to consider a revised version of your study. We cannot, of course, promise publication at that time.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition, when you are ready to resubmit, please be prepared to provide the following:

\(1\) A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\(2\) Two versions of the manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Additionally, to enhance the reproducibility of your results, PLOS recommends that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plospathogens/s/submission-guidelines#loc-materials-and-methods>
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

The question whether this enzyme is a specific menaquinone reductase is relevant. Thus, it is warranted to probe a few substrates as suggested. In addition, it is important to note that fitness was never demonstrated. Measurement of fitness by a competitive assay under the relevant in vitro conditions could substantially strengthen this work. This can be done in vitro for the hypoxia work with the appending conclusions then limited to exit from hypoxia by performing fitness assessment (competition assay of fit versus impaired fitness mutants) with analysis done by allele-specific PCR. An ideal experiment would of course be competitive experiments in mice with for example 1:5 and 5:1 ratios to see which strain gets out-competed since this would really substantiate the claims about in vivo fitness.

Reviewer\'s Responses to Questions

**Part I - Summary**

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer \#1: This manuscript by Lee and colleagues presents a careful and fairly thorough molecular and biochemical analysis of the role of Ddn variants in resistance of Mycobacterium tuberculosis to pretomanid and delamanid. The authors make the interesting observation that reduction of menaquinone (menadione), pretomanid and delamanid have distinct structural requirements. The implication of this finding is that resistance to pretomanid and delamanid can occur without ablation of native function of Ddn. Therefore, resistance need not impair fitness. Moreover, while there is overlap in some requirements for pretomanid and delamanid reduction, some variant retain activity for one but not the other. Thus, resistance to one does not necessarily confer resistance to both. Importantly, the authors interrogate numerous genome sequences from clinical isolates, many of which are not expected to have been exposed to pretomanid and delamanid. The authors are able to confirm resistance based on their variant analysis. This study is important and interesting, and the study was well designed and well presented. I have some minor suggestions to improve clarity for readers.

Reviewer \#2: This manuscript aims at predicting and understanding the role of resistance to nitroimidazole compounds by mutation in Mycobacteirum tuberculosis. One of the great strengths of this work is the use of natural polymorphisms in a large number of M. tuberculosis strains as a source of natural variability, which is of course highly relevant, given that nitroimidazole drugs will be used against such strains in practice. Most of the experiments appear to have been carefully designed, executed, analysed and interpreted.

Reviewer \#3: Background: The rapid emergence of drug resistant variants of the causative agent of tuberculosis (TB), Mycobacterium tuberculosis, has created an urgent need for new therapeutic options for this disease. Among the new and repurposed drugs that have been introduced for TB are the nitroimidazoles, delamanid and pretomanid, which are prodrugs that require activation by the deazaflavin-dependent nitroreductase (Ddn). Resistance to delamanid is acquired through mutations in the biosynthesis of F420, which serves as a cofactor for Ddn, or by direct abrogation/reduction in Ddn activity. With nitroimidazoles and another new TB drug, bedaquiline, resistance has been reported clinically in individuals who have not been exposed to the drug. Considering this, the authors set out to determine the effect of possible resistance conferring mutations on Ddn activity and the resulting resistance to nitroimidazoles.

Summary of findings: The authors first demonstrate that Ddn displays F420-dependent menaquinone-1 reductase activity that appears to be somewhat weak in vitro and they speculate the activity within the native membrane environment in M. tuberculosis is most likely enhanced. In addition to M. tuberculosis, the authors demonstrate that Ddn orthologs from a variety of mycobacterial species display menaquinone-1 reductase activity but only Ddn from M. tuberculosis and M marinum can activate nitroimidazoles. The fact that Ddn reductase activity can be found without nitroimidazole activation activity suggests that the former function is not coupled to the latter. Consistent with this, those organisms from which Ddn was unable to activate nitroimidazoles were naturally resistant to these compounds. The authors then interrogated genomes of M. tuberculosis isolates and report 46 non-synonymous substitutions and 2 deletions in ddn. They engineer these mutations and create a panel of recombinant proteins. Using this, the authors demonstrate that these mutants retained menadione reductase activity and the majority of these were also able to activate pretomanid. Ddn mutations L49P, S78Y, K79Q, W88R, and Y133C were unable to activate pretomanid, two of these - S78Y and Y113C - were able to activate delaminid. The authors conduct a phylogenetic analysis of these mutations in clinical isolates and suggest that as S78Y mutation is present in clinically successful strains, it does not have a large fitness cost. In a Beijing isolate with the S78Y mutation, the authors demonstrate robust delamanid resistance. Next, the authors create a panel of recombinant Ddn mutants with point mutations in the substrate binding site and test these for native activity and nitroimidazole activation. From the 26 mutants, all retain varying levels of menadione activity and 16 did not display the ability to activate pretomanid. Using molecular docking, the authors demonstrate that binding of pretomanid to Ddn is different to delamanid. Using mutant strains of M. tuberculosis that were selected from mice on pretomanid monotherapy and from a previous study, the authors demonstrate that some of the point mutations identified earlier (M1T, L49P, L64P, R112W, C149Y, S22L, W88R) in their analysis are sufficient to confer resistance and were associated with reduced pretomanid activation. Some of these mutants were defective in their ability to recover from hypoxia with no associated survival defects under these conditions and in the murine model of TB infection.

\*\*\*\*\*\*\*\*\*\*

**Part II -- Major Issues: Key Experiments Required for Acceptance**

Please use this section to detail the key new experiments or modifications of existing experiments that should be [absolutely]{.ul} required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a \"Major Revision\" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend \"Reject\".

Reviewer \#1: None

Reviewer \#2: The authors need to improve their description of the enzymology results and its interpretations.

For example, on the first paragraph of results, the authors \"Ddn catalyzed menaquinone reduction

in vitro with moderate efficiency (kcat/KM = 8.6 x 102 M-1 s-1)\...\". 10\^2 M-1s-1 is not moderate efficiency, it is low efficiency. One would expect a value at around 10\^6 M-1s-1 for a metabolic enzyme. Also, \" and physiologically relevant affinity (KM = 22.4 ± 3.8 μM) (Table 1);\", what is the concentration of menaquinone in the cells? Only by knowning that, the authors can judge if this is or isn\'t physiologic. Finally, Km does not equal to Kd, in most cases I have seen. Therefore, the authors must swap \"affinity\" by \"Km\".

On the second paragraph of the results, the authors leap to a conclusion without any supporting data, by stating \"Having established that Ddn is a menaquinone reductase,\...\". To this point, the authors demonstrated that Ddn can reduce menaquinone, but that does not prove that Ddn is a menaquinone reductase. To prove that, the authors must test a number of other substrates for enzymes that reduce quinone and show that kcat/Km values are smaller than what they get for menaquinone. Showing that an enzyme act (very poorly) on a substrate does not prove anything. The authors must use a variety of other quinone reductase substrates to probe the substrate specificity and therefore assign the likely bona fide substrate specificity of Ddn, if that is what they are claiming they are doing.

All other parts of the manuscript appear to be well interpreted.

Reviewer \#3: This is an exceptional biochemical analysis of amino acid sequence - structure - function relationships in Ddn with respect to its native reductase activity and the ability to activate nitroimidazoles. The study is well-executed from a biochemical perspective and has important implications for surveillance of the reported mutations in the clinical setting which would ultimately assist in better stewardship of nitroimidazoles as therapeutic agents for TB. That said, there are some shortfalls, detailed below

1\. The authors use the term fitness several times but make no substantive measure of fitness in laboratory experiments. Most conclusions are derived from clinical and epidemiological information. Several aspects may be at play in the clinical settings and these remarks should be reconsidered. The claims of fitness costs or lack thereof are not support by the data presented in this manuscript.

2\. Similarly, hypoxia seems to used interchangeably with dormancy. Dormancy is a complex phenomenon associated with metabolic quiescence. It is unclear if hypoxia in a test tube faithfully reflects this state. Moreover, recovery from such conditions in the lab is not a measure of fitness or transmissibility. This is all speculative and should be revised.

\*\*\*\*\*\*\*\*\*\*

**Part III -- Minor Issues: Editorial and Data Presentation Modifications**

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer \#1: 1. One of the interesting and important points of the manuscript is that resistance to these new bicyclic nitroimidazoles potentially occurs through genetic drift rather than by selection. The authors might consider bringing this point into the title and abstract.

2\. In author summary, change \"Strikingly, when analysed \>15,000 M. tuberculosis\...\" to \"Strikingly, when we analysed \>15,000 M. tuberculosis\...\"

3\. \"In order to spread effectively and endanger health, these resistant strains would need to retain sufficient fitness to survive all stages of the lifecycle of M. tuberculosis, including recovery from dormancy.\" Formal proof of the importance of dormancy for fitness of M. tuberculosis in the host is non-existent. We know that such populations exist, but, whether this mode is essential for transmission and pathogenesis is unknown. The authors should modify this sentence.

4\. Change \"M. tuberculosis H37Rv and M. marinum, which were the only two strains that encoded Ddn orthologs with in vitro pretomanid activation activity,\" to \"M. tuberculosis (H37Rv) and M. marinum, which were the only two species that encoded Ddn orthologs with in vitro pretomanid activation activity,\"

5\. \"Every mutant tested was able to reduce menadione, indicating that there was selective pressure to maintain the physiological function of Ddn.\" Probably true, but, without the isoprenyl tail, menadione may be a more promiscuous substrate, it is overreaching to state that this observation indicates maintenance of function, would need to test MQ (but not necessary to do this). May be better to state that it is consistent with selective pressure for maintenance of the physiological function of Ddn\...

6\. \"could readily occur and spread with sufficient selection pressure.\" to \"could readily occur and spread with sufficient selective pressure.\"

7\. \"\...will result in substantial loss of fitness given that the ability to recover from dormancy is such an important aspect of M. tuberculosis pathogenesis.\" While this might be the case, to my knowledge, there is no direct evidence, and the references provided do not provide such evidence. Maintenance of this function supports its role in fitness, but, that role might be distinct from that which has been modeled in the laboratory.

8\. \"The activation of the prodrugs pretomanid and delamanid by Ddn is a promiscuous activity that is not coupled to its native activity.\" Statement needs modification, hydride transfer is part of the native activity of Ddn

9\. \"It has long been known that promiscuous activities are more susceptible to mutation than native functions\...\" Modify, activities don\'t mutate.

10\. Figure 3 title, \"sequence\" and \"sequences\" is redundant, for figure 3 legend, should describe what color represents.

11\. Figure 4, increase font size of SNPs

12\. Table 2 seems redundant with figures that show these data. However, I do favor inclusion -perhaps as supplemental. Also, the meaning of no activity (below limit of detection?) and no expression is unclear.

13\. Table 3, rate of 0 should be expressed as less than the limit of detection. Need to define N/A, not sure why it says N/A for M. marinum when Table 2 shows activity.

14\. Table 4 seems redundant with figure 4.

15\. Same data is shown in multiple figures and tables, most journals require footnotes for repeated data.

16\. For modeling, please show top docking scores.

17\. Figure 7, replicates and statistics?

18\. Need to provide additional information for readers to understand what is presented in Table S2.

19\. Check th

Reviewer \#2: There are a few typos in the manuscript. For example, on Figure 1A (M. ulcerans, not M. ulceran) and the title of the figure (binding, not bindng).

Please, change \"Wt\" by the strain name used, as for this case, clearly H37Rv or analogous strain is not a wild-type.

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plospathogens/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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16 Dec 2019

Dear Mr Lee,

We are pleased to inform that your manuscript, \"Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering\", has been editorially accepted for publication at PLOS Pathogens. 

Before your manuscript can be formally accepted and sent to production, you will need to complete our formatting changes, which you will receive by email within a week. Please note that your manuscript will not be scheduled for publication until you have made the required changes.

IMPORTANT NOTES

\(1\) Please note, once your paper is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plospathogens@plos.org>.

\(2\) Copyediting and Proofreading: The corresponding author will receive a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. 

\(3\) Appropriate Figure Files: Please remove all name and figure \# text from your figure files. Please also take this time to check that your figures are of high resolution, which will improve the readbility of your figures and help expedite your manuscript\'s publication. Please note that figures must have been originally created at 300dpi or higher. Do not manually increase the resolution of your files. For instructions on how to properly obtain high quality images, please review our Figure Guidelines, with examples at: <http://journals.plos.org/plospathogens/s/figures>.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

\(4\) Striking Image: Please upload a striking still image to accompany your article if one is available (you can include a new image or an existing one from within your manuscript). Should your paper be accepted, this image will be considered for our monthly issue image and may also appear on our website to feature your article. Please upload this as a separate file, selecting \"striking image\" as the file type upon upload. Please also include a separate \"Other\" file with a caption, including credits and any potential copyright information. Please do not include the caption in the main article file. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License at <http://journals.plos.org/plospathogens/s/content-license>. Please note that PLOS cannot publish copyrighted images.

\(5\) Press Release or Related Media: If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team in advance at <plospathogens@plos.org> as soon as possible. We ask that you contact us within one week to plan ahead of our fast Production schedule. If you need to know your paper\'s publication date for related media purposes, you must coordinate with our press team, and your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. 

(6)  PLOS requires an ORCID iD for all corresponding authors on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager.  To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager

\(7\) Update your Profile Information: Now that your manuscript has been provisionally accepted, please log into Editorial Manager and update your profile, if needed. Go to <https://www.editorialmanager.com/ppathogens>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process. 

\(8\) LaTeX users only: Our staff will ask you to upload a TEX file in addition to the PDF before the paper can be sent to typesetting, so please carefully review our Latex Guidelines <http://journals.plos.org/plospathogens/s/latex> in the meantime.

(9) If you have associated protocols in protocols.io, please ensure that you make them public before publication to guarantee immediate access to the methodological details.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens. 

Best regards,

Helena Ingrid Boshoff

Associate Editor
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Editor-in-Chief
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Editor-in-Chief
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\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

The authors have addressed the reviewers\' concerns. This is a manuscript that describes the importance of Ddn to pathogenesis based on its role in respiration. The results demonstrate which mutations confer resistance to Pretomanid or Delamanid without impairing the respiratory function of the enzyme.

Reviewer Comments (if any, and for reference):

10.1371/journal.ppat.1008287.r004
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4 Feb 2020

Dear Mr Lee,

We are delighted to inform you that your manuscript, \"Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering,\" has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

​[orcid.org/0000-0001-5065-158X](http://orcid.org/0000-0001-5065-158X)

Michael Malim

Editor-in-Chief
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[^1]: I have read the journal\'s policy and the authors of this manuscript have the following competing interests: ELN reports a research contract from the Global Alliance for TB Drug Development and a research grant from Janssen Pharmaceuticals and collaborates on other research grants with the Global Alliance for TB Drug Development.
